PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholestero...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Xiaoming, Al Rifai, Mahmoud, Saeed, Anum, Ballantyne, Christie M, Virani, Salim S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309324/
https://www.ncbi.nlm.nih.gov/pubmed/35898405
http://dx.doi.org/10.2147/VHRM.S275739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309324/
https://www.ncbi.nlm.nih.gov/pubmed/35898405
http://dx.doi.org/10.2147/VHRM.S275739

Ejemplares similares